The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CorrectionFull Access

CORRECTION

In the article “Complementary Features of Attention Bias Modification Therapy and Cognitive-Behavioral Therapy in Pediatric Anxiety Disorders” by Lauren K. White, Ph.D., et al. (Am J Psychiatry 2017; 174:775–784) there was an error in a data point for one patient in the placebo ABMT treatment condition. Data for this patient had not been included in the imaging analyses, but were included in the randomized controlled trial (RCT) analyses. When data for the subject are removed from the analyses, the PARS ratings for the placebo ABMT group reported in Table 2 change (pretreatment: mean=16.86 [SD=3.07]; midtreatment: mean=15.35 [SD=2.89]; posttreatment: mean=13.47 [SD=3.09]) as do the CGI-I scores (midtreatment: mean=4.29 [SD=0.64]; posttreatment: mean=3.33 [SD=0.96]). Removal of this subject also changes the primary RCT analysis of the posttreatment PARS ratings differences from p=0.04, Cohen’s d=0.51 to p=0.07, Cohen’s d=0.45.